Prospective Multicenter Study Evaluating Feasibility and Efficacy of Tumor Organoid-based Precision Medicine in Patients With Advanced Refractory Cancers (ORGANOTREAT)

• ClinicalTrials.gov Identifier: NCT05267912
• Recruitment Status: Recruiting
• First Posted: March 7, 2022
• Last Update Posted: May 18, 2023
• Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
• Information provided by (Responsible Party): Gustave Roussy, Cancer Campus, Grand Paris

Study Description

Brief Summary:

• PDOs are tridimensional multicellular structures expanded in vitro which retain the genotypic and phenotypic features of their tissue or tumor of origin. PDOs can be exposed to a panel of drugs (chemotherapy, hormonal therapy, targeted therapy) in order to study their sensitivity to each agent (or combination of agents) tested ('chemogram'). Recent studies showed that PDOs can accurately predict the response to treatment of solid tumors and could therefore inform clinical decision on the best therapeutic option for each patient.
• ORGANOTREAT is a multicenter prospective study program of organoid-based precision oncology encompassing 3 studies: ORGANOTREAT-01, a pilot study restricted to advanced CRC, and ORGANOTREAT-02A and -2B, two Phase 2 studies in advanced solid cancers.

Condition or disease	Intervention/treatment	Phase
Advanced, Pretreated Solid Tumors	Procedure: Biopsy	Not Applicable

Detailed Description:

ORGANOTREAT-01, -02A and -02B

• Patients with advanced, pretreated solid cancers will be enrolled at the beginning of a standard-of-care (SoC) treatment line to allow sufficient time for PDO (tumor-derived organoid) generation and chemogram.
• A biopsy of an easily accessible tumor site will be performed.
• PDO generation, culture and amplification and drug testing will be performed.
• A chemogram report will be prepared.
• The CTB (Chemogram Tumor Board) will make treatment recommendations based on the chemogram report.
• Patients enrolled in ORGANOTREAT-01, ORGANOTREAT-02A and in the experimental arm of ORGANOTREAT-02B will be treated according to the CTB's recommendations after disease progression or unacceptable toxicity while on SoC.
• Patients will be treated at the investigator's discretion until disease progression or unacceptable toxicities. Patient will be followed until death or study termination, whichever occurs first . Note : Provide, as long as necessary (without time limit) the treatments to patient is agreed by all the centers.
• Patients for whom no chemogram can be obtained will be treated according to Soc

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 1919 participants
• Allocation: Non-Randomized
• Intervention Model: Parallel Assignment

Intervention Model Description

• ORGANOTREAT-01: advanced, pretreated colorectal cancer (CRC).
• ORGANOTREAT-02A: advanced, pretreated solid tumors of low-to-intermediate incidence and/or with a patient tumor-derived organoid (PDO) take-on rate <50%.
• ORGANOTREAT-02B: advanced, pretreated solid tumors with a PDO take-on rate ≥50%.

• Masking: None (Open Label)
• Primary Purpose: Other
• Official Title: Prospective Multicenter Study Evaluating the Feasibility and Efficacy of Tumor Organoid-based Precision Medicine in Patients With Advanced Refractory Cancers
• Actual Study Start Date: January 19, 2022
• Estimated Primary Completion Date: January 18, 2027
• Estimated Study Completion Date: January 18, 2028

Arms and Interventions

Arm	Intervention/treatment
Experimental: ORGANOTREAT 01; To assess the feasibility of timely generating chemograms from PDOs in advanced CRC. To assess the proportion of patients treated according to the chemogram tumor board (CTB)'s recommendations on the basis of their personalized chemogram. To assess the efficacy and safety of chemogram-driven treatment in advanced CRC.	Procedure: Biopsy; We need a biopsy for PDO: PDOs are tridimensional multicellular structures expanded in vitro which retain the genotypic and phenotypic features of their tissue or tumor of origin. PDOs can be exposed to a panel of drugs (chemotherapy, hormonal therapy, targeted therapy) in order to study their sensitivity to each agent (or combination of agents) tested ('chemogram'). Recent studies showed that PDOs can accurately predict the response to treatment of solid tumors and could therefore inform clinical decision on the best therapeutic option for each patient.
Experimental: ORGANOTREAT 02A; is a single-arm, Phase II study to evaluate the efficacy of chemogram-driven treatment in patients with advanced, pretreated solid cancers of low-to-intermediate incidence and/or with a PDO take-on rate <50%. The primary endpoint is the Growth Modulation Index (GMI), defined as PFSn/PFSn-1, where PFSn is the -progression-free survival (PFS) time on study treatment and PFSn-1 the PFS time within the previous treatment line.	Procedure: Biopsy; We need a biopsy for PDO: PDOs are tridimensional multicellular structures expanded in vitro which retain the genotypic and phenotypic features of their tissue or tumor of origin. PDOs can be exposed to a panel of drugs (chemotherapy, hormonal therapy, targeted therapy) in order to study their sensitivity to each agent (or combination of agents) tested ('chemogram'). Recent studies showed that PDOs can accurately predict the response to treatment of solid tumors and could therefore inform clinical decision on the best therapeutic option for each patient.
Experimental: ORGANOTREAT 02B; is a randomized Phase II study to compare the efficacy of chemogram-driven treatment vs SoC in patients with advanced, pretreated solid cancers with a PDO take-on rate ≥50%. A cross-over will allow patients enrolled in the control arm to benefit from chemogram-based treatment. Patients for whom no chemogram can be obtained will not be randomized and they will be treated according to SoC. The primary endpoint will be PFS. The study will include multiple strata, each for a different tumor type (e.g., stratum 1, pancreatic ductal adenocarcinoma (PDAC); stratum 2, CRC; etc.). Each stratum will be conducted and analyzed independently from the other strata.	Procedure: Biopsy; We need a biopsy for PDO: PDOs are tridimensional multicellular structures expanded in vitro which retain the genotypic and phenotypic features of their tissue or tumor of origin. PDOs can be exposed to a panel of drugs (chemotherapy, hormonal therapy, targeted therapy) in order to study their sensitivity to each agent (or combination of agents) tested ('chemogram'). Recent studies showed that PDOs can accurately predict the response to treatment of solid tumors and could therefore inform clinical decision on the best therapeutic option for each patient.

Outcome Measures

Primary Outcome Measures :

1. ORGANOTREAT-01: Chemogram [ Time Frame: 30 months ]
   number of patients for whom a PDO-based chemogram is obtained within 10 weeks after biopsy
2. ORGANOTREAT-02A: GMI [ Time Frame: 36 months ]
   Growth Modulation Index
3. ORGANOTREAT-02B: PFS [ Time Frame: 36 months ]
   progression free survival

Secondary Outcome Measures :

1. ORGANOTREAT-02A and -02B: chemogram [ Time Frame: 36 months ]
   proportion of patients for whom a PDO-based chemogram is obtained within 10 weeks after biopsy,
2. ORGANOTREAT-01 and -02A: PFS [ Time Frame: 36 months ]
   progression free survival
3. ORGANOTREAT-01 and -02B: GMI [ Time Frame: 36 months ]
   Growth Modulation Index
4. ORGANOTREAT-01 and -02B: ORR [ Time Frame: 36 months ]
   Overall Response Rate
5. ORGANOTREAT-01 and -02B: duration of response [ Time Frame: 36 months ]
6. ORGANOTREAT-01 and -02B: DCR [ Time Frame: 36 months ]
   Disease Control Rate
7. ORGANOTREAT-01 and -02B: duration of disease control [ Time Frame: 36 months ]
8. ORGANOTREAT-01 and -02B: clinical benefit [ Time Frame: 36 months ]
   Clinical benefit (complete response, partial response or stable disease >12 weeks according to RECIST 1.1) in patients treated according to the chemogram results
9. ORGANOTREAT-01 and -02B: OS [ Time Frame: 36 months ]
   Overall survival
10. ORGANOTREAT-01 and -02B: Number of chemogram-oriented treatment lines [ Time Frame: 36 months ]
    Number of chemogram-oriented treatment lines

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Age ≥18 years
• ECOG performance status 0-1
• Life expectancy >3 months

• Histologically-confirmed, unresectable, locally advanced or metastatic solid tumor

  • ORGANOTREAT-01: CRC
  • ORGANOTREAT-02A: solid cancers of low-to-intermediate incidence and/or with a PDO take-on rate <50%

  • ORGANOTREAT-02B: solid cancers with a PDO take-on rate ≥50%:

    • Stratum 1: PDAC
    • Stratum 2: CRC
    • Other strata: to be added by protocol amendment
• ≥1 measurable lesion according to RECIST v1.1
• ≥1 tumor site >2cm (different from the target lesion) accessible to biopsy without significant risk
• Patients are to be biopsied before the start or within the 3 first weeks of the SoC line.

• Failure (disease progression or intolerance) or contraindication to validated treatments in the advanced setting; patients MUST be still eligible for 1 (ORGANOTREAT-01 and -2A) or 2 (ORGANOTREAT-02B) validated systemic treatment lines according to approved guidelines:

  • CRC (ORGANOTREAT-01 and -02B stratum 2): failure (disease progression or intolerance) or contraindication to fluoropyrimidines, oxaliplatin, irinotecan, anti-EGFR (in RAS wild-type tumors), anti-BRAF (in BRAF V600E mutated tumors), and antiangiogenics; patients must be still eligible for trifluridine-tipiracil and/or regorafenib
  • PDAC (ORGANOTREAT-02B stratum 1): patients will be included at the beginning of their first- or second-line of therapy
  • Specifications for supplementary tumor strata in ORGANOTREAT-02 will be defined by protocol amendment
• Adequate hepatic, renal and hematological functions (AST/ALT < 2.5 ULN (5 ULN in cases of liver metastases); Total bilirubin < 1.5 ULN; Albumin > 30 g/L; International normalized ratio (INR) <1.5 ULN; Calculated creatinine clearance >50 mL/min; Absolute neutrophil count >1,000/mm^3, platelets >100,000/mm^3, hemoglobin >9 g/dL) to be performed until 7 days before enrollment
• Informed consent signed by the patient or his/her legal representative
• Affiliation to or beneficiary of a social security system

• A female participant is eligible to participate if she is not pregnant not breastfeeding, and

  1. Not a woman of childbearing potential (WOCBP) OR
  2. A WOCBP should have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
• A WOCBP must agree to follow the contraceptive guidance or abstain from heterosexual activity during the treatment period and for at least 180 days, after the last dose of treatment.

Exclusion Criteria:

• History of other invasive cancer within 5 years prior to entry into the trial other than adequately treated basal-cell skin cancer or in situ carcinoma of the cervix
• Concomitant medications/comorbidities that may prevent the patient from being biopsied
• Pregnancy or breast-feeding
• Privation of liberty or guardianship
• Geographical, social or psychological reasons precluding study participation and monitoring
• Coagulation abnormality prohibiting a biopsy
• Patients with brain or meningeal metastasis, unless definitive therapy occurred more than 6 months ago and with a confirmation of tumoral control and absence of symptoms within 4 weeks of starting study treatment

Contacts and Locations

Contacts

Contact: Michel Ducreux, MD; +33 (0)1 42 11 50 42; Michel.Ducreux@gustaveroussy.fr

Contact: Aurélie Abou Lovergne, PhD; +33 (0)1 42 11 42 11; aurelie.aboulovergne@gustaveroussy.fr

Locations

France

Gustave Roussy; Recruiting

Villejuif, France, 94805

Contact: Michel Ducreux, Pr +33 (0)1 42 11 50 42 michel.ducreux@gustaveroussy.fr

Sponsors and Collaborators

Gustave Roussy, Cancer Campus, Grand Paris

Investigators

• Study Director: Fanny Jaulin, PhD; Gustave Roussy cancer campus

More Information

• Responsible Party: Gustave Roussy, Cancer Campus, Grand Paris
• ClinicalTrials.gov Identifier: NCT05267912
• Other Study ID Numbers: 2021-A00939-32; 2021/3270 ( Other Identifier: CSET number )
• First Posted: March 7, 2022
• Last Update Posted: May 18, 2023
• Last Verified: May 2023

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No